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SUMMARY
In 1994 and 2002, respectively, the World Health Organisation proposed that treatment for hookworm and schistosomiasis
could be provided during pregnancy. It was hoped that this might have beneﬁts for maternal anaemia, fetal growth and
perinatal mortality; a beneﬁcial eﬀect on the infant response to immunisation was also hypothesised. Three trials have now
been conducted. Two have examined the eﬀects of benzimidazoles; one (the EntebbeMother and Baby Study) the eﬀects of
albendazole and praziquantel. All three were conducted in settings of high prevalence but low intensity helminth infection.
Results suggest that, in such settings and given adequate provision of haematinics, the beneﬁt of routine anthelminthics
during pregnancy for maternal anaemia may be small; none of the other expected beneﬁts has yet been demonstrated. The
EntebbeMother and Baby Study found a signiﬁcant adverse eﬀect of albendazole on the incidence of infantile eczema in the
whole study population, and of praziquantel on the incidence of eczema among infants ofmothers withSchistosomamansoni.
Further studies are required in settings that diﬀer in helminth species and infection intensities. Further research is required
to determine whether increased rates of infantile eczema translate to long-term susceptibility to allergy, and to explore the
underlying mechanisms of these eﬀects. The risks and beneﬁts of routine anthelminthic treatment in antenatal clinics may
need to be reconsidered.
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INTRODUCTION
Hookworm causes iron deﬁciency and anaemia
(Roche and Layrisse, 1966); and maternal iron
deﬁciency anaemia is associated with adverse preg-
nancy outcomes including still birth, prematurity,
low birth weight and possibly maternal mortality
(Allen, 2000). Because of this, in 1994, an informal
consultation of the World Health Organisation
(WHO) recommended that hookworm control
using levamisole or pyrantel, or the benzimidazoles
albendazole or mebendazole, should be included in
strategies for the improvement of health in girls and
women in areas where hookworm is endemic and
anaemia prevalent (WHO, 1995). In particular it was
suggested that a single dose of anthelminthic treat-
ment could be given in pregnancy, during the second
to third trimester; routine anthelminthic treatment
was already being implemented during antenatal care
in Sri Lanka (Atukorala et al. 1994; de Silva et al.
1999). However, at that time no randomised trials to
assess the risks and beneﬁts of this intervention had
been undertaken.
A further consultation in 2002 considered the use
of praziquantel during pregnancy and lactation
(WHO, 2002); previous recommendations had been
against this. The consultation recognised that the
former recommendations could result in exclusion of
women in endemic areas from treatment of schisto-
somiasis for a large proportion of their reproductive
lives. It was proposed that as well as speciﬁc end-
organ damage, schistosomiasis in pregnancy might
contribute to important subtle maternal morbidity
including anaemia and decreased work capacity, and
perhaps to impaired fetal growth. There was no
evidence of fetal toxicity for praziquantel in animals,
and its use during human pregnancy in a small
number of documented cases had shown no severe
adverse eﬀects. Therefore the consultation recom-
mended the use of praziquantel during pregnancy.
Again, no randomised trials of praziquantel treat-
ment during pregnancy had been undertaken and
in 2006 a WHO working group on schistosomiasis
listed among its priorities to “conduct without delay
randomised, placebo-controlled trials of praziquantel
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treatment in pregnancy for all species of human
schistosome in areas of both high and low trans-
mission” (WHO, 2006).
Since these meetings, two randomised trials on
the use of benzimidazoles during pregnancy have
been reported (Haider et al. 2009), one from Peru
(Larocque et al. 2005, 2006) and one from Sierra
Leone (Torlesse and Hodges, 2001), and in Uganda
we have conducted a randomised trial of both
albendazole and praziquantel during pregnancy,
using a 2×2 factorial design: the Entebbe Mother
and Baby Study (Elliott et al. 2007). We here
summarise the results of our trial, with follow-up of
infants to one year of age, and discuss the implications
of our ﬁndings, and of the ﬁndings of other recent
studies, for recommendations on the routine use
of anthelminthic drugs during pregnancy, and for
further research priorities.
The Entebbe Mother and Baby Study
[ISRCTN32849447]
Although the WHO consultations focused mainly on
potential beneﬁts for anaemia and helminth-speciﬁc
pathology in the mother and for growth in the
fetus, there are other important potential eﬀects of
helminths and anthelminthic treatment during preg-
nancy. Helminths have a major impact on the host
immune system, modulating the response both to
themselves and to unrelated antigens (van Riet et al.
2007). Before the start of our trial, it had been
observed that exposure tomaternal helminths in utero
could result in sensitisation of the fetus to helminth
antigens (Novato-Silva et al. 1992; Malhotra et al.
1997), and in modulation of the infant immune
response to neonatal BCG immunisation (Malhotra
et al. 1999). The Entebbe Mother and Baby Study
was therefore designed to address the hypothesis
that helminth infections can inﬂuence the immune
response to non-worm antigens (including immuno-
gens and pathogens), that these eﬀects can be
established in utero and that they can be modiﬁed
by anthelminthic treatment during pregnancy.
The study commenced in 2002 as a trial of
albendazole versus placebo during pregnancy, but
was suspended following publication of the WHO
recommendations on use of praziquantel during
pregnancy (Allen et al. 2002) and modiﬁed to allow
us to investigate eﬀects of praziquantel treatment
during pregnancy, as well as of albendazole treat-
ment. Data collected before this modiﬁcation created
a preliminary study of the eﬀects of albendazole
treatment during pregnancy among 104 mothers and
their infants. In this preliminary study we observed
a protective eﬀect of maternal helminth infection,
and a possible detrimental eﬀect of albendazole
treatment during pregnancy, on the incidence of
infantile eczema (Elliott et al. 2005). Therefore we
alsomodiﬁed the trial design to allow us to investigate
eﬀects of anthelminthics during pregnancy on
allergic disease outcomes.
The main Entebbe Mother and Baby Study thus
compared single-dose albendazole (400 mg) versus
placebo and praziquantel (40 mg/kg) versus placebo,
given during the second or third trimester of preg-
nancy, in a 2×2 factorial design. All women were
treated with both albendazole and praziquantel after
delivery. The study included a further randomisation
of the children, from age 15 months to ﬁve years, to
quarterly albendazole versus placebo; this part of the
study will be completed in 2011 and will not be
discussed in this review.
The study is based in Entebbe and the neighbour-
ing sub-county of Katabi, a peninsula in Lake
Victoria, Uganda. We recruited 2507 women at the
government district hospital between 2003 and 2005.
Mostwomenwere poor: 82% reported amonthly cash
income of less than 30,000 Uganda shillings (then
approximately US$20) per month. They came from
the relatively urban setting of Entebbe Municipality
and from the surrounding ﬁshing communities
and rural farming communities. The prevalence of
helminth infection at enrolment was high: 68% had at
least one helminth infection, 45% had hookworm,
21% M. perstans and 18% had Schistosoma mansoni;
other species were less common (Woodburn et al.
2009). For intestinal helminths these results were
based on examination of two slides from a single
stool sample, implying that the true prevalence of
helminths was higher (Hall, 1981; Utzinger et al.
2001). Although the prevalence of infection was high,
intensity was generally low, according to WHO
classiﬁcations (WHO, 1995, 1999): 85% of those
with hookworm had egg counts below 1000 eggs per
gram (epg) of stool (91% below 2000 epg), and 65% of
those with S. mansoni had counts below 100 epg.
At age one year, only 44 of 1358 infants examined had
helminth infections, the commonest being Ascaris
(15 infants), Trichuris (12 infants) and Mansonella
(eight infants); because these numbers were so small
the eﬀects of infants’ helminth infections are not
considered further in this review.
EFFECTS OF ANTHELMINTHIC TREATMENT
IN PREGNANCY
On helminth prevalence
Anthelminthic treatment duringpregnancywas eﬀec-
tive in our study (Ndibazza et al. 2010) (Fig. 1). The
prevalence of hookworm declined in the albendazole
treatment group from 45% to 5%. This was similar to
the eﬀect of albendazole reported by Torlesse and
Hodges, (2001) but greater than the eﬀect reported by
Larocque et al. (2006) for single-dose mebendazole,
in accord with the greater eﬃcacy of albendazole
against hookworm (Keiser and Utzinger, 2008).
There was no change in hookworm prevalence in
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the albendazole placebo group. Single-dose albenda-
zole was also eﬀective for Ascaris, but had little
eﬀect on Stronglyloides or Trichuris. Praziquantel
was eﬀective against S. mansoni: prevalence declined
from 18% to 5%. This is important because preg-
nancy is associated with immunosuppression and
the eﬃcacy of praziquantel may depend partly on
immunologically-mediated killing following disrup-
tion of the tegument and exposure of antigens on the
surface of the parasite (Doenhoﬀ et al. 2008). We
found that boosts in cytokine and antibody response
to schistosome antigens after treatment tended to be
lower when praziquantel was given during pregnancy
than when it was given after delivery, but the cure
rate for S. mansoni was similar (Tweyongyere et al.
2008, 2009).
On maternal anaemia
TheWHO consultations discussed above anticipated
that reductions in anaemia would be an important
beneﬁt of intervention against hookworm during
pregnancy, and also a beneﬁt of treating schisto-
somiasis during pregnancy. In our study, the
prevalence of anaemia at baseline was 40%. No
individual helminth species was associated with the
presence of anaemia, but increasing intensity of
hookworm was associated with lower haemoglobin
level (Muhangi et al. 2007). These ﬁndings were
similar to those of Larocque et al. (2005) in Peru,
where the prevalence and intensity of hookworm
infection were similar. By contrast to a study in
Tanzania (Ajanga et al. 2006), we found no associ-
ation at baseline between maternal anaemia and
intensity of S. mansoni.
We provided haematinics routinely to all women,
as well as two doses of intermittent presumptive treat-
ment for malaria with sulphadoxine-pyrimethamine.
We found no overall beneﬁt of anthelminthic treat-
ment during pregnancy on maternal anaemia after
delivery and no beneﬁt of albendazole in the
subgroup of mothers shown to have hookworm at
baseline, or of praziquantel among mothers shown to
have S. mansoni infection (Ndibazza et al. 2010). An
exploratory analysis stratiﬁed for hookworm intensity
suggested a possible beneﬁt of albendazole among
women with moderate to heavy hookworm, but this
diﬀerence in eﬀect was not statistically signiﬁcant.
Again, the ﬁndings of Larocque et al. (2006) were
similar: no beneﬁt for maternal anaemia in the
context of the provision of haematinics. The Sierra
Leone trial (Torlesse and Hodges, 2001) compared
single-dose albendazole with haematinics in a fac-
torial design and found some beneﬁt of albendazole
but a greater beneﬁt of haematinics for both anaemia
and iron status. Together, these results suggest
that, given adequate provision of haematinics, the
beneﬁt of routine anthelminthics during pregnancy
for maternal anaemia may be less than had been
anticipated.
On birth weight
The possibility that birth weight would be improved
by routine treatment with benzimidazoles during
pregnancy in areas of high hookworm prevalence
was suggested by the cross-sectional study in Sri
Lanka (de Silva et al. 1999). Very low birth weight
(below 1·5 kg) was less common among women
who reported taking mebendazole during pregnancy
than among those that did not. Similarly, a non-
randomised study of albendazole treatment in Nepal
suggested a beneﬁt for birth weight (Christian et al.
2004). The principal limitation of these studies was
the possibility that taking anthelminthics was associ-
ated with better overall care-seeking behaviour and
hence better outcomes mediated by a variety of
factors. More recently, studies in animals suggested
possible adverse eﬀects of schistosomiasis on birth
weight and other perinatal outcomes, but no adequate
studies have been conducted to explore similar eﬀects
in humans (Friedman et al. 2007).
Neither we nor Larocque et al. (2006) found any
beneﬁt of anthelminthic treatment during pregnancy
Fig. 1. Prevalence of the three commonest helminth infections at enrolment and after delivery, according to treatment
allocation during pregnancy, among 2507 women participating in the Entebbe Mother and Baby Study. Placebo: double
placebo group; alb: single dose albendazole (400mg) plus placebo for praziquantel; praz: single dose praziquantel
(40mg/kg) plus placebo for albendazole; alb+praz: single dose albendazole (400mg) plus praziquantel (40mg/kg).
Error bars show the upper 95% conﬁdence interval for the percentage prevalence of infection.
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for mean birth weight or low birth weight (below
2·5 kg) (Ndibazza et al. 2010). Larocque and col-
leagues found a possible beneﬁt of mebendazole for
very low birth weight (below 1·5 kg), but only seven
infants fell into this category in their study. In our
study, 11 infants were very low birth weight and there
was no association between this outcome and the
treatment the mother had received. Again, the pro-
vision of adequate haematinics could be a factor in
preventing an adverse eﬀect of hookworm mediated
by iron deﬁciency, and a consequent beneﬁt of
albendazole, from becoming evident, but the role of
iron and folic acid supplementation in determining
pregnancy outcomes other than anaemia remains
uncertain (Pena-Rosas and Viteri, 2006).
On congenital anomalies
The principal mode of action of benzimidazoles is to
bind tubulin and inhibit the synthesis of micro-
tubules which are ubiquitous components of the
eukaryotic cytoskeleton. Their speciﬁcity for hel-
minths is relative and selectivity seems to be related to
the stability of binding between the drug and the
tubulin molecules (Lacey, 1990; MacDonald et al.
2004). Thus interference with processes such as
mitosis provide a plausible mechanism of fetal
toxicity for benzimidazoles, and there is evidence of
toxicity in animal models (Dayan, 2003). Although
this was recognised by the WHO committee in 1995,
diﬀerences in dose, metabolism and pharmaco-
kinetics between animal models and human usage
led them to suggest that benzimidazoles were
probably safe for pregnant and lactating women and
their oﬀspring (WHO, 1995). In the cross-sectional
study in Sri Lanka, the number of congenital
anomalies was higher among infants of women
who reported taking mebendazole during the ﬁrst
trimester than among those that did not, but this
diﬀerence was not statistically signiﬁcant (de Silva
et al. 1999) and, overall, observational studies
have not reported a signiﬁcant excess of congenital
anomalies following use of benzimidazoles in human
pregnancy (Diav-Citrin et al. 2003).
The mode of action of praziquantel is less certain
(Doenhoﬀ et al. 2008), but for this drug there is
no evidence of genotoxicity or fetal toxicity (Dayan,
2003; Adam et al. 2005).
We avoided anthelminthic treatment during the
ﬁrst trimester, and found no evidence of association
between either albendazole or praziquantel and
congenital anomalies in our study (Ndibazza et al.
2010). Similarly, the trials in Peru and Sierra Leone
found no evidence of fetal toxicity for benzimidazoles
given in the second trimester (Torlesse and Hodges,
2001; Larocque et al. 2006). These ﬁndings are
encouraging, but pharmacovigilance remains appro-
priate, especially if anthelminthics are given in the
ﬁrst trimester.
On perinatal and infant mortality
The observational studies in Sri Lanka and Nepal
suggested a beneﬁt of benzimidazoles during preg-
nancy for perinatal mortality and infant survival to
6 months of age (de Silva et al. 1999; Christian et al.
2004). However, we found no beneﬁt of either
albendazole or praziquantel during pregnancy for
rates of still birth, neonatal mortality or infant
mortality (Ndibazza et al. 2010; Webb et al. 2011).
Similarly, Larocque et al. (2006) found no eﬀect of
mebendazole on perinatal mortality.
On infant response to immunisation
The evidence that led to the hypothesis that antenatal
exposure to helminth infections has an important
inﬂuence on the infant response to immunisation in
low-income and tropical settings has been reviewed
elsewhere (Labeaud et al. 2009). As discussed above,
this hypothesis was the principal motivation for our
study.We used a six-day whole blood culture assay at
age one year to assess the cellular response to BCG
and tetanus immunisation, stimulated using crude
culture ﬁltrate proteins ofMycobacterium tuberculosis
and tetanus toxoid (TT), respectively; we examined
production of type 1 (interferon (IFN)-γ) type 2
(interleukin (IL)-5 and IL-3) and regulatory (IL-10)
cytokines in supernatant using enzyme-linked im-
munosorbent assays (ELISAs). ELISAs were also
used to assess antibody responses to TT and measles
immunisation.
We found no overall eﬀect of either treatment on
the response to immunisation (Webb et al. 2011).
In sub-group analyses we found a reduction in type 2
cytokine responses to tetanus toxoid among infants of
mothers with hookworm who received albendazole,
compared to those who received placebo, but there
was no eﬀect on total immunoglobulin (Ig)G
production, the key parameter for protection follow-
ing tetanus immunisation (Plotkin, 2010). No other
eﬀects were observed for the response to BCG,
tetanus or measles immunisation in the planned sub-
group analyses for eﬀects of albendazole in mothers
with hookworm, or of praziquantel in mothers with
S. mansoni. Such results could occur if eﬀects of
helminth exposure were established prior to the
trial intervention, say during the ﬁrst trimester,
and could not be reversed by subsequent treatment.
This explanation is unlikely since, in observational
analyses, infant response to vaccines showed no
consistent associations with the presence of maternal
hookworm or S. mansoni (Elliott et al. 2010).
In observational analyses, maternal infection with
the ﬁlarial helminth,Mansonella perstans, was associ-
ated with increased IL-10 responses to the vaccine
antigens. Curiously, this eﬀect was evident princi-
pally in the albendazole placebo group, although
Mansonella prevalence was not aﬀected by the single
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dose of albendazole given. Maternal Mansonella
showed no eﬀect on type 1 or type 2 responses
(Elliott et al. 2010).
Taken together, our results suggest that maternal
helminth infection is unlikely to be a major con-
tributor to poor eﬃcacy of immunisation in infancy
in the tropics, and routine anthelminthic treatment
during pregnancy is unlikely to lead to important
improvements in this outcome.
On infectious disease incidence in infancy
There is considerable evidence, both from animal
models and from studies in humans, that exposure to
helminths in utero programmes the infant response
to subsequent challenge, inﬂuencing susceptibility to
infection, and immunologically-mediated pathology
(Lammie et al. 1991; Steel et al. 1994; Malhotra
et al. 2006). Pursuing the idea that some of the
immunoregulatory eﬀects of helminthsmay inﬂuence
responses to bystander antigens, we investigated
whether anthelminthic treatment during pregnancy
inﬂuenced infant susceptibility to infectious diseases.
We found no eﬀect on incidence of malaria or on
malaria infection at age one year; and no eﬀect on
incidence of diarrhoea or lower respiratory tract
infection (Webb et al. 2011).
In two previous studies concerning helminths and
HIV infection, we had noted a temporary increase
in HIV load following treatment of S. mansoni
(Elliott et al. 2003; Brown et al. 2005), so a particular
concern was that treatment with praziquantel during
pregnancy might result in increased intrauterine
HIV transmission. Our study had little power to
assess this outcome and was inconclusive, but vertical
HIV transmission was, if anything, lower among
HIV-positive mothers that received praziquantel
(OR 0·60 (95% CI 0·29–1·23)) (Webb et al. 2011).
On allergy
There is considerable evidence from animal models,
and some from studies in humans, that helminth
infection can protect against allergic disease through
active immunoregulatory pathways (Smits et al.
2010). The results of epidemiological studies to date
have been less clear-cut. In cross-sectional studies
atopy (represented by skin-prick test positivity) has
shown a fairly consistent inverse association with
helminth infection, and hookworm has shown a
consistent inverse association with asthma, but
associations with asthma for other helminths, and
associations between helminths and eczema, have
been variable (Leonardi-Bee et al. 2006; Flohr et al.
2009). Some, but not all, intervention studies have
shown an eﬀect of anthelminthic treatment on skin-
prick test responses to allergens but, prior to our
study, none had shown an eﬀect on an allergic disease
outcome (Lynch et al. 1993; van den Biggelaar et al.
2004; Cooper et al. 2006; Endara et al. 2010; Flohr
et al. 2010).
In the Entebbe Mother and Baby Study, eczema
was the commonest allergic condition observed
during infancy, as expected for the age group, with
an incidence of 10 per 100 person years of follow-up.
In a sub-group of infants for whom skin-prick testing
was conducted, eczema was strongly associated with
skin prick test positivity, indicating that it was atopic.
We found that albendazole treatment during preg-
nancy was associated with an increased risk of eczema
in the whole study population (Cox proportional
Hazard Ratio (HR) 1·82 (95% CI 1·26–2·64)), while
praziquantel treatment was associated with increased
risk of eczema among infants of mothers with
S. mansoni (HR 2·65 (95% CI 1·16–6·08), interaction
P value 0·02) (Mpairwe et al. 2011) (Fig. 2).
For albendazole, we expected that the eﬀects
would be strongest among infants of women with
hookworm – the commonest species, and most sus-
ceptible to albendazole treatment – but, surprisingly,
stratiﬁcation by maternal hookworm status showed
no diﬀerence in eﬀect (interaction P value 0·52).
Indeed, an eﬀect of albendazole was seen even among
infants of mothers with no detected helminth
infection. This may mean that the eﬀect of albenda-
zole was mediated (a) by the drug itself, (b) by an
eﬀect on low intensity hookworm, or other albenda-
zole-susceptible helminth species, not detected by
the single stool sample examined or (c) by an eﬀect on
another organism. Albendazole has a broad spectrum
of action, sometimes overlooked in relation to anthel-
minthic treatment programmes, and candidates
for option (c) include malaria, intestinal protozoa,
microsporidia and commensal yeasts (Cruz and
Edlind, 1997; Skinner-Adams et al. 1997; Mac-
Donald et al. 2004; Solaymani-Mohammadi et al.
2010).
By contrast, our ﬁndings for schistosomiasis are
entirely consistent with a protective eﬀect of exposure
to maternal S. mansoni infection that is removed by
praziquantel treatment.
Our study is thus the ﬁrst to demonstrate an eﬀect
of anthelminthic treatment on an allergic disease
outcome and provides support for the hypothesis
that helminths protect against allergic disease. Why
did we observe an eﬀect, while previous studies in
school-age children did not? Given the low preva-
lence of allergic disease in rural tropical environ-
ments, several of the previous studies had limited
power to show an eﬀect on disease outcomes.
However, an important possibility is that our study
showed an eﬀect because susceptibility to allergic
disease is programmed in utero or very early in post-
natal life, with relatively little eﬀect of subsequent
intervention (vonMutius andLe Souef, 2007). Thus,
from the perspective of allergology, our results
provide important evidence that pre-natal or very
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early post-natal interventions may allow the primary
prevention of allergic disease in children at risk.
CONCLUSIONS AND FURTHER RESEARCH NEEDS
The Entebbe Mother and Baby Study is the ﬁrst
randomised, double-blind, placebo-controlled trial
of praziquantel treatment during pregnancy. It is also
the ﬁrst trial to examine the eﬀects of praziquantel
or of benzimidazole treatment during pregnancy
on the broad range of maternal and infant outcomes
that might be inﬂuenced by pre-natal exposure to
helminths. Some of the long-term eﬀects of anthel-
minthic treatment during pregnancy, including
eﬀects on the oﬀspring’s own susceptibility to infec-
tion andmorbidity when exposed to the same species,
have yet to be examined. However, the results to
date, taken together with the ﬁndings of other recent
studies, suggest that the risks and beneﬁts of anthel-
minthic treatment during pregnancy, and policy
regarding routine provision of anthelminthics during
antenatal care, may need to be reviewed.
In Entebbe, where good, general antenatal care
was provided, there was a possible beneﬁt of
albendazole for anaemia in mothers with moderate
to heavy hookworm infection, but otherwise none of
the expected beneﬁts of anthelminthic treatment on
anaemia, birth weight, perinatal mortality, infant
Fig. 2. The eﬀect of treatment with albendazole or praziquantel during pregnancy on the incidence of eczema during
infancy in the Entebbe Mother and Baby Study. (A) The eﬀect of albendazole among 2345 live-born infants of all
mothers, with or without detected helminth infection. (B) The eﬀect of praziquantel among 421 infants of mothers with
detected Schistosoma mansoni infection. Shown are the cumulative hazard functions based on multiple eczema events.
Alb, albendazole; praz, praziquantel.
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mortality or infant response to immunisation were
realised. These ﬁndings were in keeping with results
from the two other benzimidazole trials (Torlesse and
Hodges, 2001; Larocque et al. 2006). Mothers with
possible symptomatic helminth infection were ex-
cluded from our trial, but such women were unusual
in our setting: of 11,783 screened for the study only
17 were excluded for haemoglobin below 8 g/dl,
15 for diarrhoea with blood in stools and none for
clinically apparent severe liver disease (Webb et al.
2011). It other settings, or with other helminth
species (for example S. japonicum), the balance of
beneﬁts to mother and infant may diﬀer. However,
the minimal eﬀects associated with helminths and
anthelminthic treatment in our setting are put fur-
ther into perspective by the strong adverse eﬀects of
malaria and HIV infection observed; the prevalence
of malaria was 13% and of HIV 12% at baseline,
during pregnancy, in our study. We found that
maternal malaria and HIV infection were strongly
associated with maternal anaemia (Muhangi et al.
2007), and were also associated with reduced birth
weight and increased perinatal mortality (unpub-
lished data). Maternal and infant HIV infection,
and infant malaria, were associated with deleterious
eﬀects on the infant response to immunisation
(Elliott et al. 2010).
The three trials have been conducted to date in
areas with high hookworm prevalence but low
intensity, and this is the common pattern of helminth
infection. However, a trial in a setting with heavy
hookworm infection might have a diﬀerent result,
especially if background levels of nutrition and iron
status are poor. Trial results might also be expected
to diﬀer according to helminth species: Necator
americanus and Ancylostoma duodenale may diﬀer
in their pathogencity for anaemia (Albonico et al.
1998) – and we have not yet determined the prevalent
species in Entebbe; schistosome species clearly diﬀer
in the immunopathology that they induce (Burke
et al. 2009). The three reported studies demonstrate
that placebo-controlled trials can be conducted
safely, and additional trials are still needed in diﬀer-
ent settings.
The observed adverse eﬀect on infantile eczema is a
concern, and contributes to the current equipoise in
evidence regarding the potential risks and beneﬁts of
anthelminthic therapy during pregnancy. Whether
this ﬁnding can be generalised to other environments
is uncertain: Entebbe is unusual among lake-shore
communities in Uganda in being relatively urbanised
and traversed by a major highway, and hosting the
international airport. Pollutants may contribute to
the induction of allergy (Venn et al. 2001, 2005), and
the results of anthelminthic therapy in such a setting
may diﬀer from the results in a purely rural context.
A key question is whether eﬀects on infantile
eczema will this translate into an impact on asthma in
later life? Studies in aﬄuent countries suggest that
while infantile eczema per se may not predict later
asthma, early development of atopy, and eczema
associated with atopy and wheeze in early childhood,
may be associated with atopic asthma at school-age
(Illi et al. 2004, 2006; Williams and Flohr, 2006).
Asthma mortality depends not just on prevalence,
but also on quality of care; already 80% of asthma
deaths occur in low- and middle-income countries
(WHO, 2010). It is possible that, as low-income
countries develop, anthelminthic treatment pro-
grammes will contribute to an epidemic increase in
allergic disease similar to that experienced in aﬄuent
countries during the 20th century (Bach, 2002).
Further research is needed to determine whether this
is likely to be the case; if so, measures to equip such
countries to manage such an epidemic need to be
planned.
Conversely, studies of the underlying mechanisms
of helminth-allergy interactions in endemic countries
have the potential to provide insights for the develop-
ment of new tools for the prevention and manage-
ment of allergic disease, with global health beneﬁts.
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